The granting of a patent for ABVC BioPharma's treatment of Major Depressive Disorder in Taiwan could potentially increase the company's market share and revenues in the future. This is because the patent would protect the company's intellectual property, allowing it to exclusively sell and profit from the treatment in Taiwan. This could lead to increased demand for the company's shares, potentially driving up the stock price in the short term.